What is the NOAEL for 2-Nitro-1,4-phenylenediamine?
2-Nitro-1,4-phenylenediamine has 31 NOAEL studies in the database. The lowest reported value is 0 % via Dermal. Source: NTP_ICE_skin_sensitization.
Also known as: 2-Nitro-p-phenylenediamine, 3-13-00-00271, BRN 2210195, CI Oxidation Base 22, Durafur Brown (+12 more)
CAS 5307-14-2
2-Nitro-1,4-phenylenediamine (CAS 5307-14-2) is a chemical substance; key hazard signal: IARC Group 3. Key regulatory status: REACH registered, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, IARC, ECHA REACH, ILO ICSC.
View cosmetic safety profile for 2-Nitro-P-Phenylenediamine →
2-Nitro-1,4-phenylenediamine is prohibited in EU cosmetics but has active industrial GHS classifications (H315, H317, H319, H335, H302).
CAS, identifiers, formula, and alternate names for the matched substance record.
Carcinogenic hazard classification from IARC monograph evaluations.
| Group | Meaning | Evaluated | Volume |
|---|---|---|---|
| Group 3 | Not classifiable | 1992 | Sup 7, 57 |
International Chemical Safety Card hazard and exposure summary.
| Field | Value |
|---|---|
| Long-term Effects | Repeated or prolonged contact may cause skin sensitization. |
| Routes of Exposure | The substance can be absorbed into the body through the skin. |
Industrial and product-use categories associated with this substance.
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 276.7 | ug/mL | CD54, EC200 | Dermal | - | NTP_ICE_skin_sensitization |
| 5.42 | ug/mL | CD86, EC150 | Dermal | - | NTP_ICE_skin_sensitization |
| 6.8 | ug/mL | CD86, EC150 | Dermal | - | NTP_ICE_skin_sensitization |
| 115.49 | ug/mL | CV70 | Dermal | - | NTP_ICE_skin_sensitization |
| 490.7 | ug/mL | CV75 | Dermal | - | NTP_ICE_skin_sensitization |
| 93.3 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 99.2 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| - | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 5.7 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 46.7 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 50 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 11.464 | uM | EC1.5 | Dermal | - | NTP_ICE_skin_sensitization |
| 0.4 | % | EC3 | Dermal | Mouse | NTP_ICE_skin_sensitization |
| 0.4 | % | EC3 | Dermal | Mouse | NTP_ICE_skin_sensitization |
| 0.4 | % | EC3 | Dermal | Mouse | NTP_ICE_skin_sensitization |
| 0.4 | % | EC3 | Dermal | Mouse | NTP_ICE_skin_sensitization |
| 786.4 | uM | EC3 | Dermal | - | NTP_ICE_skin_sensitization |
| PV83F3C01Q | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| PV83F3C01Q | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| PV83F3C01Q | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| PV83F3C01Q | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | unitless | IARC group | - | - | NTP_ICE_cancer |
| >2000 | uM | IC50 | Dermal | - | NTP_ICE_skin_sensitization |
| 4.53 | ratio | Imax | Dermal | - | NTP_ICE_skin_sensitization |
| =1800 | mg/kg bw | LD50 | oral | Rat (Male/Female) | NTP_ICE_acute_oral |
| =2100 | mg/kg bw | LD50 | oral | Rat (Male) | NTP_ICE_acute_oral |
| =3080 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| 1100 | ppm | Top dose | - | Rat | NTP_ICE_cancer |
| 2200 | ppm | Top dose | - | Rat | NTP_ICE_cancer |
| 4400 | ppm | Top dose | - | Mouse | NTP_ICE_cancer |
Showing 31 of 31 studies
Registration status from the ECHA REACH registered substances database.
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | 2-nitro-p-phenylenediamine | 226-164-5 | ECHA overview → |
Australian industrial chemicals inventory status and applicable conditions.
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
2-Nitro-1,4-phenylenediamine has 31 NOAEL studies in the database. The lowest reported value is 0 % via Dermal. Source: NTP_ICE_skin_sensitization.
2-Nitro-1,4-phenylenediamine is classified by IARC as Group 3 — not classifiable as to its carcinogenicity to humans (evaluated 1992). Source: IARC Monographs on the Identification of Carcinogenic Hazards to Humans.
Yes, 2-Nitro-1,4-phenylenediamine is also indexed as a cosmetic ingredient under the name 2-Nitro-P-Phenylenediamine. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, IARC Monographs, ECHA REACH, ILO/WHO ICSC, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
2-Nitro-1,4-phenylenediamine is prohibited in EU cosmetics but has active industrial GHS classifications (H315, H317, H319, H335, H302).
2-Nitro-1,4-phenylenediamine also appears in cosmetics, pharmaceutical databases.